A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.

Exclusion Criteria

• •History or family history of drug allergy
• •Subjects treated with any other anti-diabetes drug within 8 weeks before screening
• •Participation in any other clinical trial of an investigational medicinal product within 3 months before screening
• •Smoker or alcohol abuse
• •Currently use or plan to use systemic corticosteroid
• •History of recurrent severe hypoglycemia
• •Type 1 diabetes or secondary diabetes mellitus
• •Uncontrolled active or untreated hypertension
• •History of pancreatitis (acute or chronic)
• •Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary Thyroid Carcinoma (MTC)
• •Serious unconscious hypoglycemia history
• •Within the past 6 months before screening any of the following: coronary artery revascularization, patients presently classified as being in New York Heart Association (NYHA) Class III or IV, myocardial infarction, stroke or unstable angina and/or persistent and clinically significant arrhythmias
• •Female subject of childbearing potential who does not use an acceptable method of birth control, is pregnant or planning a pregnancy, or breastfeeding, or male subject who does not use an acceptable method of birth control
• •Subject was not used for the study as determined by the Investigator